Indolinones and anilinophthalazines differentially target VEGF-A- and basic fibroblast growth factor-mediated responses in primary human endothelial cells

British Journal of Pharmacology

Volumn 165, Issue 1, 2012, Pages 245-259

  Latham, A M ^a   Bruns, A F ^a   Kankanala, J ^a   Johnson, A P ^a   Fishwick, C W G ^a   Homer Vanniasinkam, S ^b   Ponnambalam, S ^a  

^a UNIVERSITY OF LEEDS   (United Kingdom)

^b LEEDS GENERAL INFIRMARY   (United Kingdom)

Author keywords

angiogenesis; endothelium; FGFR1; kinase inhibitor; VEGFR2

Indexed keywords

FIBROBLAST GROWTH FACTOR 2; FIBROBLAST GROWTH FACTOR RECEPTOR 1; PROTEIN TYROSINE KINASE; SEMAXANIB; SUNITINIB; VASCULOTROPIN A; VASCULOTROPIN RECEPTOR 2; VATALANIB;

ANTIANGIOGENIC ACTIVITY; ARTICLE; BIOCHEMISTRY; CELL MIGRATION; CELL PROLIFERATION; CELL TRANSFORMATION; COMPUTER MODEL; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFICACY; DRUG PROTEIN BINDING; DRUG TARGETING; ENDOTHELIAL DYSFUNCTION; ENZYME ACTIVATION; ENZYME ACTIVE SITE; ENZYME ASSAY; FIBROBLAST; HELA CELL; HINGE REGION; HUMAN; HUMAN CELL; IN VITRO STUDY; INHIBITION KINETICS; INTRACELLULAR SIGNALING; MICROSCOPY; MOLECULAR DOCKING; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN STRUCTURE; PROTEIN TRANSPORT; TUBULOGENESIS; UMBILICAL VEIN ENDOTHELIAL CELL; WOUND HEALING;

ADENOSINE TRIPHOSPHATE; CATALYTIC DOMAIN; COMPUTER SIMULATION; ENDOTHELIAL CELLS; FIBROBLAST GROWTH FACTOR 2; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; HUMANS; INDOLES; MODELS, BIOLOGICAL; MODELS, MOLECULAR; PHTHALAZINES; PROTEIN BINDING; PROTEIN CONFORMATION; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 1; SIGNAL TRANSDUCTION; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 82955189749     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2011.01545.x     Document Type: Article

References (47)

1. Ali MA, Bhogal N, Findlay JB, Fishwick CW, (2005). The first de novo-designed antagonists of the human NK(2) receptor. J Med Chem 48: 5655-5658. (Pubitemid 41298339)
2. Antoine M, Wirz W, Tag CG, Mavituna M, Emans N, Korff T, et al,. (2005). Expression pattern of fibroblast growth factors (FGFs), their receptors and antagonists in primary endothelial cells and vascular smooth muscle cells. Growth Factors 23: 87-95. (Pubitemid 43203056)
3. Arora A, Scholar EM, (2005). Role of tyrosine kinase inhibitors in cancer therapy. J Pharmacol Exp Ther 315: 971-979. (Pubitemid 41635382)
4. Bae JH, Boggon TJ, Tome F, Mandiyan V, Lax I, Schlessinger J, (2010). Asymmetric receptor contact is required for tyrosine autophosphorylation of fibroblast growth factor receptor in living cells. Proc Natl Acad Sci USA 107: 2866-2871.
5. Blanes MG, Oubaha M, Rautureau Y, Gratton JP, (2007). Phosphorylation of tyrosine 801 of vascular endothelial growth factor receptor-2 is necessary for Akt-dependent endothelial nitric-oxide synthase activation and nitric oxide release from endothelial cells. J Biol Chem 282: 10660-10669. (Pubitemid 47093458)
6. Bruns AF, Herbert SP, Odell AF, Jopling HM, Hooper NM, Zachary IC, et al,. (2010). Ligand-stimulated VEGFR2 signaling is regulated by co-ordinated trafficking and proteolysis. Traffic 11: 161-174.
7. Carmeliet P, (2003). Angiogenesis in health and disease. Nat Med 9: 653-660. (Pubitemid 36749213)
8. Chow LQ, Eckhardt SG, (2007). Sunitinib: from rational design to clinical efficacy. J Clin Oncol 25: 884-896. (Pubitemid 350002890)
9. Eskens FA, (2004). Angiogenesis inhibitors in clinical development; where are we now and where are we going? Br J Cancer 90: 1-7. (Pubitemid 38174929)
10. Ewan LC, Jopling HM, Jia H, Mittar S, Bagherzadeh A, Howell GJ, et al,. (2006). Intrinsic tyrosine kinase activity is required for vascular endothelial growth factor receptor 2 ubiquitination, sorting and degradation in endothelial cells. Traffic 7: 1270-1282. (Pubitemid 44204001)
11. Ferrara N, Gerber HP, Lecouter J, (2003). The biology of VEGF and its receptors. Nat Med 9: 669-676. (Pubitemid 36749215)
12. Finetti F, Solito R, Morbidelli L, Giachetti A, Ziche M, Donnini S, (2008). Prostaglandin E2 regulates angiogenesis via activation of fibroblast growth factor receptor-1. J Biol Chem 283: 2139-2146.
13. Fong TA, Shawver LK, Sun L, Tang C, App H, Powell TJ, et al,. (1999). SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types. Cancer Res 59: 99-106. (Pubitemid 29062964)
14. Friesner RA, Banks JL, Murphy RB, Halgren TA, Klicic JJ, Mainz DT, et al,. (2004). Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy. J Med Chem 47: 1739-1749. (Pubitemid 38380917)
15. Garfinkel S, Hu X, Prudovsky IA, McMahon GA, Kapnik EM, McDowell SD, et al,. (1996). FGF-1-dependent proliferative and migratory responses are impaired in senescent human umbilical vein endothelial cells and correlate with the inability to signal tyrosine phosphorylation of fibroblast growth factor receptor-1 substrates. J Cell Biol 134: 783-791. (Pubitemid 26269147)
16. Harris PA, Boloor A, Cheung M, Kumar R, Crosby RM, Davis-Ward RG, et al,. (2008). Discovery of 5-[[4-[(2,3-dimethyl-2H-indazol-6-yl)methylamino]-2- pyrimidinyl]amino]-2-methyl-benzenesulfonamide (Pazopanib), a novel and potent vascular endothelial growth factor receptor inhibitor. J Med Chem 51: 4632-4640.
17. Hasinoff BB, Patel D, (2010). The lack of target specificity of small molecule anticancer kinase inhibitors is correlated with their ability to damage myocytes in vitro. Toxicol Appl Pharmacol 249: 132-139.
18. Holmes K, Roberts OL, Thomas AM, Cross MJ, (2007). Vascular endothelial growth factor receptor-2: structure, function, intracellular signalling and therapeutic inhibition. Cell Signal 19: 2003-2012. (Pubitemid 47354167)
19. Howell GJ, Herbert SP, Smith JM, Mittar S, Ewan LC, Mohammed M, et al,. (2004). Endothelial cell confluence regulates Weibel-Palade body formation. Mol Membr Biol 21: 413-421. (Pubitemid 40030217)
20. Jain KK, (2007). Cancer biomarkers: current issues and future directions. Curr Opin Mol Ther 9: 563-571. (Pubitemid 350179096)
21. Jubb AM, Oates AJ, Holden S, Koeppen H, (2006). Predicting benefit from anti-angiogenic agents in malignancy. Nat Rev Cancer 6: 626-635. (Pubitemid 44140860)
22. Karaman MW, Herrgard S, Treiber DK, Gallant P, Atteridge CE, Campbell BT, et al,. (2008). A quantitative analysis of kinase inhibitor selectivity. Nat Biotechnol 26: 127-132.
23. Knights V, Cook SJ, (2010). De-regulated FGF receptors as therapeutic targets in cancer. Pharmacol Ther 125: 105-117.
24. Latham AM, Molina-Paris C, Homer-Vanniasinkam S, Ponnambalam S, (2010). An integrative model for vascular endothelial growth factor A as a tumour biomarker. Integr Biol (Camb) 2: 397-407.
25. Lin B, Podar K, Gupta D, Tai YT, Li S, Weller E, et al,. (2002). The vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK222584 inhibits growth and migration of multiple myeloma cells in the bone marrow microenvironment. Cancer Res 62: 5019-5026. (Pubitemid 34984429)
26. Los M, Roodhart JM, Voest EE, (2007). Target practice: lessons from phase III trials with bevacizumab and vatalanib in the treatment of advanced colorectal cancer. Oncologist 12: 443-450. (Pubitemid 46698722)
27. Mendel DB, Laird AD, Smolich BD, Blake RA, Liang C, Hannah AL, et al,. (2000a). Development of SU5416, a selective small molecule inhibitor of VEGF receptor tyrosine kinase activity, as an anti-angiogenesis agent. Anticancer Drug Des 15: 29-41. (Pubitemid 30364897)
28. Mendel DB, Schreck RE, West DC, Li G, Strawn LM, Tanciongco SS, et al,. (2000b). The angiogenesis inhibitor SU5416 has long-lasting effects on vascular endothelial growth factor receptor phosphorylation and function. Clin Cancer Res 6: 4848-4858. (Pubitemid 32110429)
29. Mendel DB, Laird AD, Xin X, Louie SG, Christensen JG, Li G, et al,. (2003). In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res 9: 327-337. (Pubitemid 36109749)
30. Murakami M, Elfenbein A, Simons M, (2008). Non-canonical fibroblast growth factor signalling in angiogenesis. Cardiovasc Res 78: 223-231. (Pubitemid 351556091)
31. Noble ME, Endicott JA, Johnson LN, (2004). Protein kinase inhibitors: insights into drug design from structure. Science 303: 1800-1805. (Pubitemid 38374863)
32. Nourse MB, Rolle MW, Pabon LM, Murry CE, (2007). Selective control of endothelial cell proliferation with a synthetic dimerizer of FGF receptor-1. Lab Invest 87: 828-835. (Pubitemid 47077262)
33. Oguro Y, Miyamoto N, Takagi T, Okada K, Awazu Y, Miki H, et al,. (2010). N-phenyl-N'-[4-(5H-pyrrolo[3,2-d]pyrimidin-4-yloxy)phenyl]ureas as novel inhibitors of VEGFR and FGFR kinases. Bioorg Med Chem 18: 7150-7163.
34. Olsson AK, Dimberg A, Kreuger J, Claesson-Welsh L, (2006). VEGF receptor signalling-in control of vascular function. Nat Rev Mol Cell Biol 7: 359-371.
35. Rini BI, Small EJ, (2005). Biology and clinical development of vascular endothelial growth factor-targeted therapy in renal cell carcinoma. J Clin Oncol 23: 1028-1043. (Pubitemid 46202321)
36. Roskoski R Jr, (2007). Sunitinib: a VEGF and PDGF receptor protein kinase and angiogenesis inhibitor. Biochem Biophys Res Commun 356: 323-328. (Pubitemid 46452568)
37. Schoeberl B, Eichler-Jonsson C, Gilles ED, Muller G, (2002). Computational modeling of the dynamics of the MAP kinase cascade activated by surface and internalized EGF receptors. Nat Biotechnol 20: 370-375. (Pubitemid 34286330)
38. Shalaby F, Rossant J, Yamaguchi TP, Gertsenstein M, Wu XF, Breitman ML, et al,. (1995). Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice. Nature 376: 62-66.
39. Takahashi T, Shibuya M, (1997). The 230 kDa mature form of KDR/Flk-1 (VEGF receptor-2) activates the PLC-gamma pathway and partially induces mitotic signals in NIH3T3 fibroblasts. Oncogene 14: 2079-2089. (Pubitemid 27237011)
40. Takamoto T, Sasaki M, Kuno T, Tamaki N, (2001). Flk-1 specific kinase inhibitor (SU5416) inhibited the growth of GS-9L glioma in rat brain and prolonged the survival. Kobe J Med Sci 47: 181-191. (Pubitemid 34101040)
41. Tanghetti E, Ria R, Dell'Era P, Urbinati C, Rusnati M, Ennas MG, et al,. (2002). Biological activity of substrate-bound basic fibroblast growth factor (FGF2): recruitment of FGF receptor-1 in endothelial cell adhesion contacts. Oncogene 21: 3889-3897. (Pubitemid 34620857)
42. Tasker AS, Patel VF, (2008). Discovery of motesanib. DOI:10.2210/pdb3efl/ pdb.
43. Tille JC, Wood J, Mandriota SJ, Schnell C, Ferrari S, Mestan J, et al,. (2001). Vascular endothelial growth factor (VEGF) receptor-2 antagonists inhibit. J Pharmacol Exp Ther 299: 1073-1085.
44. Turner N, Grose R, (2010). Fibroblast growth factor signalling: from development to cancer. Nat Rev Cancer 10: 116-129.
45. Wood JM, Bold G, Buchdunger E, Cozens R, Ferrari S, Frei J, et al,. (2000). PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration. Cancer Res 60: 2178-2189. (Pubitemid 30225181)
46. Zhang J, Yang PL, Gray NS, (2009). Targeting cancer with small molecule kinase inhibitors. Nat Rev Cancer 9: 28-39.
47. Zhou T, Commodore L, Huang WS, Wang Y, Sawyer TK, Shakespeare WC, et al,. (2010). Structural analysis of DFG-in and DFG-out dual Src-Abl inhibitors sharing a common vinyl purine template. Chem Biol Drug Des 75: 18-28.